


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the present application:

Listing of Claims:

1 - 10. (Canceled)

11. (Previously presented): A method for treating a cardiovascular disease in a mammal suffering therefrom, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)




to the mammal.

12. (Previously presented): The method according to Claim 11, wherein the mammal is a human.

13. (Previously presented): A method for treating a disease chosen from unstable angina pectoris, acute coronary syndrome, heart failure, myocardial infarction, thrombosis, peripheral artery occlusive disease, restenosis, and endothelial damage after PTCA in a mammal suffering therefrom, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl


benzamide according to the formula (I)



to the mammal.

14. (Previously presented): The method according to Claim 13, wherein the mammal is a human.

15. (Previously presented): A method for treating a cardiovascular disease in a mammal suffering therefrom, which method comprises administering a pharmaceutical preparation comprising an effective amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)




and a pharmaceutically acceptable carrier to the mammal.

16. (Previously presented): The method according to Claim 15, wherein the mammal is a human.

17. (Previously presented): The method according to Claim 15, wherein the pharmaceutical preparation is in the form of a pill, tablet, granule, hard or soft gelatin capsule, aqueous, alcoholic or oily solution, syrup, emulsion or suspension, suppository, solution for injection or infusion, ointment, tincture, spray, transdermal therapeutic system, nasal spray, aerosol mixture, microcapsule, implant or rod.

18. (Previously presented): The method according to Claim 17, wherein the tablet is chosen from a lacquered tablet and a sugar-coated tablet.

19. (Previously presented): A method for treating a disease chosen from unstable angina pectoris, acute coronary syndrome, heart failure, myocardial infarction, thrombosis, peripheral artery occlusive disease, restenosis, and endothelial damage after PTCA in a mammal suffering therefrom, which method comprises administering a pharmaceutical preparation comprising an effective amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)



and a pharmaceutically acceptable carrier to the mammal.


20. (Previously presented): The method according to Claim 19, wherein the mammal is a human.

21. (Currently amended): The method according to Claim [20] 19, wherein the pharmaceutical preparation is in the form of a pill, tablet, granule, hard or soft gelatin capsule, aqueous, alcoholic or oily solution, syrup, emulsion or suspension, suppository, solution for injection or infusion, ointment, tincture, spray, transdermal therapeutic system, nasal spray, aerosol mixture, microcapsule, implant or rod.

22. (Previously presented): The method according to Claim 21, wherein the tablet is chosen from a lacquered tablet and a sugar-coated tablet.

23. (Previously presented): A method for treating erectile dysfunction or osteoporosis in a mammal suffering therefrom, which method comprises administering a


physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)



to the mammal.

24. (Previously presented): The method according to Claim 23, wherein the mammal is a human.

25. (Previously presented): A method for treating erectile dysfunction or osteoporosis in a mammal suffering therefrom, which method comprises administering a pharmaceutical preparation comprising an effective amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)



and a pharmaceutically acceptable carrier to the mammal.

26. (Previously presented): The method according to Claim 25, wherein the mammal is a human.

27. (Previously presented): The method according to Claim 25, wherein the pharmaceutical preparation is in the form of a pill, tablet, granule, hard or soft gelatin capsule, aqueous, alcoholic or oily solution, syrup, emulsion or suspension, suppository, solution for injection or infusion, ointment, tincture, spray, transdermal therapeutic system, nasal spray, aerosol mixture, microcapsule, implant or rod.

28. (Previously presented): The method according to Claim 27, wherein the tablet is chosen from a lacquered tablet and a sugar-coated tablet.